Printer Friendly

Research and Markets: Erythropoietin, Current Market Dynamics & Future Outlook.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c9341) has announced the addition of Erythropoietin, Current Market Dynamics & Future Outlook to their offering.

By the end of 2003 the world market for erythropoietin was valued at $10.3 billion, a growth of 14% over 2002. The market has been growing at an average annual growth rate of 21% over the previous 5 years. The market for Erythropoietin is very lucrative. Marketing costs are low due to the well-defined patient population and distribution costs are low due to the limited distribution outlets. Since the market is a virtual oligopoly barriers to entry are high thus insuring high profitability. Although patent fortification in the US limits competition in this market opportunities are still available for new comers. Epoetin Alfa key patents starts to expire in the US in October 2004 and in Europe in December 2004.

Already generic products have been developed and is currently being marketed in Asia, Latin America and Eastern Europe. With such a huge market at stakes both large multinationals such as Novartis's Sandoz biogenerics division and large generics producers such as Ratiopharm of Germany are eyeing the market. Many new and emerging dedicated biogenerics companies are also eyeing the market and some of them have already launched their products in selected niche markets. Many licensing opportunities for fully developed generics versions of epoetin alfa are available.

Written with the senior executive needs in mind, Erythropoietin - Current Market Dynamics & Future outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics or in Biogenerics.

For more information visit http://www.researchandmarkets.com/reports/c9341
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 15, 2004
Words:274
Previous Article:CompTIA Cybercast Focuses on Readying Organizations for RFID Deployment.
Next Article:ACE Limited Announces Executive Appointments in Europe And Bermuda.


Related Articles
Rescuing red cells to boost blood supply.
Honey, I shrank the hormone.
New tests may catch bicyclers on dope.
BUSINESS NOTES AMGEN SUED OVER $31.9 MILLION BILL.
AMGEN GETS PATENT FOR PROTEIN TO FIGHT DIALYSIS ANEMIA.
Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment. (Case Report).
Protein may aid stroke recovery.
Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent.
Blood, iron, and gray hair: anemia in old age is a rising concern.
Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight...

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters